80582-04-3

Basic information

• Product Name: (3S-trans)-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-2-azetidinone
• Synonyms: (3S-trans)-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-2-azetidinone
• CAS NO: 80582-04-3
• Molecular Weight: 234.255
• Mol File: 80582-04-3.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: (3S-trans)-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-2-azetidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (3S-trans)-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-2-azetidinone(80582-04-3)
• EPA Substance Registry System: (3S-trans)-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-2-azetidinone(80582-04-3)

Safety Data

• Hazardous Substances Data: 80582-04-3(Hazardous Substances Data)

Upstream product

• 112026-40-1 cis-3-benzyloxycarbonylamino-N-(4-methoxyphenyl)-4-methylazetidin-2-one 
• 112026-39-8 ethyl 3-(p-anisidino)-2-(benzyloxycarbonylamino)butanoate 
• 112026-38-7 ethyl (p-anisidino)-2-(benzoyloxycarbonylamino)but-2-enoate 
• 112026-37-6 ethyl 2-(benzyloxycarbonylamino)acetoacetate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 80082-62-8 (3S-trans)-2-Oxo-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-1-azetidinesulfonic acid,tetrabutylammonium salt 
• 19728-63-3 N-benzyloxycarbonyl-L-treonine 
• 80582-03-2 (3S-trans)-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-2-azetidinone 
• 501-53-1 benzyl chloroformate 
• 126448-46-2 (2R,3S)-3-Benzyloxycarbonylamino-4-oxo-1-((S)-1-phenyl-ethyl)-azetidine-2-carboxylic acid methyl ester 
• 117082-72-1 [(2R,3S)-2-Hydroxymethyl-4-oxo-1-((S)-1-phenyl-ethyl)-azetidin-3-yl]-carbamic acid benzyl ester 
• 90497-66-8 [(3R,4S)-1-(tert-Butyl-dimethyl-silanyl)-2-oxo-4-phenylsulfanyl-azetidin-3-yl]-carbamic acid benzyl ester 
• 99705-36-9 ((3R,4S)-2-Oxo-4-phenylsulfanyl-azetidin-3-yl)-carbamic acid benzyl ester 
• 139111-01-6 (1'R,3S,4R)-3-(benzyloxycarbonylamino)-4-(1'-tert-butyldimethylsilyloxy-ethyl)-azetidin-2-one 

Downstream Products

• 112334-88-0 (2S-trans)-[1-[[[[3-[[[1,4-Dihydro-4-oxo-5-(phenylmethoxy)-2-pyridinyl]carbonyl]amino]-2-oxo-1-imidazolidinyl]sulfonyl]amino]carbonyl]-2-methyl4-oxo-3-azetidinyl]carbamic acid, phenylmethyl ester 
• 102652-80-2 ((2S,3S)-2-Methyl-4-oxo-3-phenylacetylamino-azetidin-1-ylsulfanyl)-acetic acid tert-butyl ester 
• 102652-82-4 <<4(S)-methyl-3-(S)-((benzyloxy)formamido)-2-oxo-1-azetidinyl>thio>acetic acid 
• 87791-62-6 (3S,4S)-3-amino-4-methyl-azetidin-2-one 
• 100239-04-1 tert-butyl <<4(S)-methyl-3(S)-((benzyloxy)formamido)-2-oxo-1-azetidinyl>thio>acetate 
• 136918-14-4 phthalimide 
• 100239-05-2 S-<4(S)-methyl-3(S)-((benzyloxy)formamido)-2-oxo-1-azetidinyl>-N-(carboboenzyloxy)-L-cysteine methyl ester 
• 87791-64-8 4(S)-methyl-3(S)-(phenylacetamido)-2-azetidinone 
• 100239-03-0 methyl <<4(S)-methyl-3(S)-((benzyloxy)formamido)-2-oxo-1-azetidinyl>thio>acetate 
• 80082-62-8 (3S-trans)-2-Oxo-3-[[(phenylmethoxy)carbonyl]amino]-4-methyl-1-azetidinesulfonic acid,tetrabutylammonium salt 
• 80082-62-8 (2R,3S)-3-Benzyloxycarbonylamino-2-methyl-4-oxo-azetidine-1-sulfonatetetrabutyl-ammonium; 

Relevant articles and documents

Heteroatom-activated β-lactam antibiotics: Considerations of differences in the biological activity of [[3(S)-(acylamino)-2-oxo-1-azetidinyl]oxy]acetic acids (oxamazins) and the corresponding sulfur analogues (thiamazins)

-

Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2

Aztreonam, first discovered in 1980, is an FDA approved, intravenous, monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative bacteria and is still used today. The oral bioavailability of aztreonam in humans is less than 1%. Herein we describe the design and synthesis of potential oral prodrugs of aztreonam.

AZTREONAM DERIVATIVES AND USES THEREOF

Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with β-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.